Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

33%

4 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

6(54.5%)

Phase 3

4(36.4%)

N/A

1(9.1%)

11Total

Phase 2(6)

Phase 3(4)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT06556563Phase 3Recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Role: lead

NCT05624918Phase 2Recruiting

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Role: collaborator

NCT02973789Phase 3Completed

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Role: lead

NCT07319910Unknown

Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)

Role: lead

NCT06216301Phase 3Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Role: lead

NCT02831959Phase 3Completed

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Role: lead

NCT06558799Phase 2Active Not Recruiting

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT04892472Phase 2Terminated

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Role: lead

NCT04492163Phase 2Completed

Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM

Role: lead

NCT04671459Phase 2Unknown

TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine

Role: collaborator

NCT04223999Phase 2Recruiting

Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)

Role: collaborator

NCT04953234Not ApplicableCompleted

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge

Role: lead

All 12 trials loaded